Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:36 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Treatment of Cushing's Disease With R-roscovitine
NCT02160730 · Shlomo Melmed, MD · PHASE2 · terminated · last registry update 2021-11-04 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “NIH grant ended.” | – | Registry record, Shlomo Melmed, MD |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against CDK2 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2022-10-21Results posted on the registry: Sumitomo Pharma America, Inc., Alvocidib Plus Decitabine (during dose escalation only) or Azacitidine (NCT03593915)
- 2022-10-19Results posted on the registry: Sumitomo Pharma America, Inc., Alvocidib (flavopiridol) and cytarabine (Ara-C) + Alvocidib (flavopiridol) (NCT03969420)
- 2021-12-22Also stopped (terminated): Cyclacel Pharmaceuticals, Inc., seliciclib + placebo (NCT00372073)
- 2021-09-28Results posted on the registry: National Cancer Institute (NCI), Zotiraciclib (TG02) + Temozolomide (TMZ) (NCT02942264)
- 2021-07-15Results posted on the registry: Sumitomo Pharma America, Inc., Alvocidib + Cytarabine (NCT02520011)
- 2021-05-24Results posted on the registry: Sumitomo Pharma America, Inc., Alvocidib + Cytarabine (NCT03298984)
- 2021-04-08Also stopped (terminated): Bayer, Roniciclib (BAY1000394) + Etoposide (NCT01573338)
- 2021-03-01Results posted on the registry: Merck Sharp & Dohme LLC, pembrolizumab + dinaciclib (NCT02684617)
- 2021-03-01Also stopped (terminated): Merck Sharp & Dohme LLC, pembrolizumab + dinaciclib (NCT02684617)
- 2020-11-12Also stopped (withdrawn): M.D. Anderson Cancer Center, Alvocidib Hydrochloride + Decitabine (NCT04493099)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision